# Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes

> **NIH NIH P01** · BRIGHAM AND WOMEN'S HOSPITAL · 2022 · $533,326

## Abstract

Program Director/Principal Investigator (Last, First, Middle):Kwiatkowski, David J. et al., Project 2: Cantley and Shaw
Abstract
Over the past five years it has become clear that many tumors rewire their metabolism to support rapid growth,
but that the molecular details of how each tumor rewires its metabolism depends on the unique oncogenes and
tumor suppressors that dominantly control metabolism, which include all of the hamartoma syndrome genes, as
the PI3K/ mTOR/ LKB1 pathways play a major role in metabolic control in normal and cancer cells. The focus
of this project is to better understand metabolic vulnerabilities and provide preclinical data that would support the
development of biomarker driven clinical trials to evaluate such drugs in patients with germline or the many
tumors containing sporadic mutations in hamartoma syndrome genes (PTEN, LKB1, TSC1, TSC2).

## Key facts

- **NIH application ID:** 10460141
- **Project number:** 5P01CA120964-15
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** David J. Kwiatkowski
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $533,326
- **Award type:** 5
- **Project period:** 2006-12-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10460141

## Citation

> US National Institutes of Health, RePORTER application 10460141, Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes (5P01CA120964-15). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10460141. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*